Sequential early-life viral infections modulate the microbiota and adaptive immune responses to systemic and mucosal vaccination.

Sequential early-life viral infections modulate the microbiota and adaptive immune responses to systemic and mucosal vaccination.

Publication date: Oct 02, 2024

Increasing evidence points to the microbial exposome as a critical factor in maturing and shaping the host immune system, thereby influencing responses to immune challenges such as infections or vaccines. To investigate the effect of early-life viral exposures on immune development and vaccine responses, we inoculated mice with six distinct viral pathogens in sequence beginning in the neonatal period, and then evaluated their immune signatures before and after intramuscular or intranasal vaccination against SARS-CoV-2. Sequential viral infection drove profound changes in all aspects of the immune system, including increasing circulating leukocytes, altering innate and adaptive immune cell lineages in tissues, and markedly influencing serum cytokine and total antibody levels. Beyond changes in the immune responses, these exposures also modulated the composition of the endogenous intestinal microbiota. Although sequentially-infected mice exhibited increased systemic immune activation and T cell responses after intramuscular and intranasal SARS-CoV-2 immunization, we observed decreased vaccine-induced antibody responses in these animals. These results suggest that early-life viral exposures are sufficient to diminish antibody responses to vaccination in mice, and highlight the potential importance of considering prior microbial exposures when investigating vaccine responses.

Open Access PDF

Concepts Keywords
Host Adaptive
Increasing Antibody
Mice Early
Mucosal Exposures
Vaccines Immune
Increasing
Infections
Life
Microbiota
Responses
Sequential
Systemic
Vaccination
Vaccine
Viral

Semantics

Type Source Name
disease MESH viral infections
disease IDO host
pathway REACTOME Immune System
disease MESH infections
disease IDO cell
disease MESH Infectious Diseases
pathway REACTOME Reproduction
disease IDO reagent
disease MESH COVID 19
disease IDO bacteria
disease IDO pathogen
disease IDO replication
disease IDO susceptibility
disease IDO infection
drug DRUGBANK Yellow Fever Vaccine
disease IDO intervention
disease MESH Herpesvirus infections
disease MESH latent infections
disease MESH influenza
disease IDO blood
drug DRUGBANK Pentaerythritol tetranitrate
disease IDO assay
drug DRUGBANK Proline
disease MESH viral shedding
pathway KEGG Viral replication
disease MESH leukocytosis
drug DRUGBANK Methacholine
drug DRUGBANK Methylergometrine
disease IDO history
disease MESH yellow fever
drug DRUGBANK Tretamine
disease IDO protein
disease MESH chronic infection
disease IDO acute infection
disease MESH hepatitis
drug DRUGBANK Water
drug DRUGBANK Edetic Acid
drug DRUGBANK Honey
drug DRUGBANK Hyaluronic acid
pathway REACTOME Digestion
drug DRUGBANK Collagenase clostridium histolyticum
drug DRUGBANK Methylcellulose
drug DRUGBANK Phenol
drug DRUGBANK Ademetionine
drug DRUGBANK Magnesium sulfate
drug DRUGBANK Platinum
drug DRUGBANK Amlodipine
pathway REACTOME Release

Original Article

(Visited 1 times, 1 visits today)